a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantationEnsayo aleatorio, abierto para estudiar la eficacia de risedronato 35mg/semanal en la prevención de pérdida de masa ósea y calcificaciones vasculares post-trasplante renal - PREVENOS

Dr. Jose Vicente Torregrosa Prats (fundacio clinic)0 个研究点开始时间: 2006年1月24日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Male and female aged 18-75 years old; chronic renal failure's patients on dialysis that have had a kidney transplant; patients who have been fully informed and have given written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Hyperimmunized patients (PRA ›75%); multiorganic transplant; diabetes mellitus patients on insulin treatment at the transplant moment; parathyroidectomised patients with parathyroid hormone values ‹ 50 pg/ml; patients that have received fluorine, biphosphonates or hormone replacement therapy in the previous 6 months, antiepileptic or calcitonin treatment in the previous 3 months, patients with biphosphonate allergy history, dyspepsia or reflux history and pregnant patients or nursing mothers.

发起方

Dr. Jose Vicente Torregrosa Prats (fundacio clinic)